{
    "clinical_study": {
        "@rank": "99012", 
        "arm_group": [
            {
                "arm_group_label": "Aprepitant Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Dosing will be based on age and weight.  The dose given will be the adult equivalent of 125 mg aprepitant.\nA single dose of aprepitant (oral [PO]) and placebo matching ondansetron (intravenous [IV]) will be administered prior to induction of anesthesia."
            }, 
            {
                "arm_group_label": "Aprepitant Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Dosing will be based on age and weight.  The dose given will be the adult equivalent of 40 mg aprepitant.\nA single dose of aprepitant (PO) and placebo matching ondansetron (IV) will be administered prior to induction of anesthesia."
            }, 
            {
                "arm_group_label": "Aprepitant Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "Dosing will be based on age and weight.  The dose given will be the adult equivalent of 10 mg aprepitant.\nA single dose of aprepitant (PO) and placebo matching ondansetron (IV) will be administered prior to induction of anesthesia."
            }, 
            {
                "arm_group_label": "Aprepitant Dose 4", 
                "arm_group_type": "Experimental", 
                "description": "Dosing will be based on age and weight.  The dose given will be the adult equivalent of 2.5 mg aprepitant.\nA single dose of aprepitant (PO) and placebo matching ondansetron (IV) will be administered prior to induction of anesthesia.\nThis dose will not be tested if submaximal efficacy is detected."
            }, 
            {
                "arm_group_label": "Ondansetron", 
                "arm_group_type": "Active Comparator", 
                "description": "4 mg for participants >40 kg in weight; 0.1 mg/kg for participants \u226440 kg in weight.  In participants <1 month of age, the dose of ondansetron will be administered per the product label or based on local standard of care.\nA single dose of ondansetron (IV) and placebo matching aprepitant (PO)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the appropriate dosing regimen of aprepitant for\n      the prevention of post-operative nausea and vomiting in pediatric participants birth to 17\n      years."
        }, 
        "brief_title": "A Study to Evaluate Aprepitant for the Prevention of Post Operative Nausea and Vomiting in Children (MK-0869-219 AM3)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Post-Operative Nausea", 
            "Post-Operative Vomiting"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting", 
                "Postoperative Nausea and Vomiting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participant enrolled at birth should be at least 37 weeks gestation and \u22653 kg of\n             weight\n\n          -  Scheduled to receive general anesthesia AND must have at least one of the following\n             risk factors for post-operative nausea and vomiting (PONV) in addition to receiving\n             general anesthesia:\n\n               1. scheduled to have a surgery with an associated risk of PONV: tonsillectomy,\n                  adenoidectomy, strabismus surgery, dental surgery, hydrocelectomy, orchidopexy\n                  or herniorraphy; OR\n\n               2. scheduled to have an operative procedure associated with PONV:\n\n        intraoperative opioid use or anticipated opioid administration within the first 24 hours\n        following surgery.\n\n        Exclusion Criteria:\n\n          -  Emergency surgery for a life-threatening condition\n\n          -  Scheduled to receive propofol for maintenance of anesthesia (Note: propofol is\n             permitted for induction of anesthesia).\n\n          -  Expected to receive opioid antagonists (e.g., naloxone, naltrexone) or\n\n        benzodiazepine antagonists (e.g., flumazenil)\n\n          -  Scheduled to undergo cardiac or neurosurgery\n\n          -  Vomiting caused by any organic etiology (such as gastric outlet\n\n        obstruction or small bowel obstruction)\n\n          -  Vomiting within 24 hours prior to surgery\n\n          -  Nasogastric or oral gastric tube intra- or post-operatively for suctioning\n\n        gastric contents\n\n          -  Active infection (e.g., pneumonia), congestive heart failure,\n\n        bradyarrythmia, any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal\n        obstruction) except for malignancy, or a history of any illness which in the opinion of\n        the investigator, might confound the results of the study or pose unwarranted risk to the\n        participant\n\n          -  Use of any illicit drugs, including marijuana or has current evidence of alcohol\n             abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "260", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732458", 
            "org_study_id": "0869-219", 
            "secondary_id": "2011-006006-27"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Aprepitant Dose 1", 
                    "Aprepitant Dose 2", 
                    "Aprepitant Dose 3", 
                    "Aprepitant Dose 4"
                ], 
                "intervention_name": "Aprepitant", 
                "intervention_type": "Drug", 
                "other_name": [
                    "MK-0869", 
                    "EMEND\u2122"
                ]
            }, 
            {
                "arm_group_label": "Ondansetron", 
                "intervention_name": "Placebo to match aprepitant", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ondansetron", 
                "intervention_name": "Ondansetron", 
                "intervention_type": "Drug", 
                "other_name": "Zofran"
            }, 
            {
                "arm_group_label": [
                    "Aprepitant Dose 1", 
                    "Aprepitant Dose 2", 
                    "Aprepitant Dose 3", 
                    "Aprepitant Dose 4"
                ], 
                "intervention_name": "Placebo to match ondansetron", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ondansetron", 
                "Aprepitant"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "Call for Information (Investigational Site 0031)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43606"
                    }, 
                    "name": "Call for Information (Investigational Site 0030)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78723"
                    }, 
                    "name": "Call for Information (Investigational Site 0032)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ricardo Germano", 
                    "phone": "55 11 51897942"
                }, 
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "MSD Brasil"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Medical Information Centre / Centre de l'information medicale de Merck Canada", 
                    "phone": "514-428-8600 / 1-800-567-2594"
                }, 
                "facility": {
                    "address": {
                        "city": "Kirkland", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H9H 3L1"
                    }, 
                    "name": "Merck Canada"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Simona Martinkova", 
                    "phone": "420 233010213"
                }, 
                "facility": {
                    "address": {
                        "city": "Praha", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Merck Sharp and Dohme s.r.o."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Soraya Cedraro", 
                    "phone": "507-282-7200"
                }, 
                "facility": {
                    "address": {
                        "city": "Guatemala", 
                        "country": "Guatemala"
                    }, 
                    "name": "MSD CARD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Simona Martinkova", 
                    "phone": "36 1 457 8522"
                }, 
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "MSD Pharma Hungary Kft."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Patrizia Nardini", 
                    "phone": "39 06 361911"
                }, 
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "MSD Italia S.r.l."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Juan Marques", 
                    "phone": "52 55254819608"
                }, 
                "facility": {
                    "address": {
                        "city": "Mexico City", 
                        "country": "Mexico"
                    }, 
                    "name": "MSD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Felipe Arbelaez", 
                    "phone": "(787) 474-8200"
                }, 
                "facility": {
                    "address": {
                        "city": "Carolina", 
                        "country": "Puerto Rico"
                    }, 
                    "name": "Merck Sharp & Dohme (I.A.) Corp."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Maria Koroleva", 
                    "phone": "7 0959410000"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Merck Sharp & Dohme IDEA, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Khanyi Mzolo", 
                    "phone": "27 11 655 3140"
                }, 
                "facility": {
                    "address": {
                        "city": "Midrand", 
                        "country": "South Africa"
                    }, 
                    "name": "MSD (Pty) LTD South Africa"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cesar Sanz Rodriguez", 
                    "phone": "34 913210600"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Merck Sharp and Dohme de Espana S.A."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alev Eren", 
                    "phone": "90 212 336 12 63"
                }, 
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey"
                    }, 
                    "name": "Merck Sharp & Dohme Ilaclari Ltd. Sti"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Brazil", 
                "Canada", 
                "Czech Republic", 
                "Guatemala", 
                "Hungary", 
                "Italy", 
                "Mexico", 
                "Puerto Rico", 
                "Russian Federation", 
                "South Africa", 
                "Spain", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase IIb, Partially-Blinded, Randomized, Active Comparator- Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the Prevention of Post Operative Nausea and Vomiting", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum (peak) plasma drug concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Time to maximum observed plasma concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero to infinity (AUC[0-\u221e])", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Apparent total clearance of the drug from plasma after oral administration (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Aprepitant Terminal Phase Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "removed_countries": {
            "country": [
                "Chile", 
                "Peru"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732458"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}